The company have informed us that they are no longer seeking regulatory approval in this indication. Therefore the appraisal is suspended.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 821
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Stakeholders
- Companies sponsors
- Chugai Pharma (anamorelin)
- Helsinn (anamorelin)
- Others
- Department of Health
- NHS England
- NHS Ipswich and East Suffolk CCG
- NHS Southwark CCG
- Welsh Government
- Patient carer groups
- Black Health Agency
- British Lung Foundation
- Cancer Black Care
- Cancer Equality
- HAWC
- Helen Rollason Cancer Charity
- Independent Cancer Patients Voice
- Macmillan Cancer Support
- Maggie’s Centres
- Marie Curie
- Muslim Council of Britain
- Roy Castle Lung Cancer Foundation
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Tenovus Cancer Care
- UK Lung Cancer Coalition
- Professional groups
- Association of Cancer Physicians
- Association of Respiratory Nurse Specialists
- British Dietetic Association
- British Geriatrics Society
- British Institute of Radiology
- British Psychosocial Oncology Society
- British Thoracic Oncology Group
- British Thoracic Society
- Cancer Research UK
- National Lung Cancer Forum for Nurses
- Primary Care Respiratory Society UK
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- UK Clinical Pharmacy Association
- UK Health Forum
- UK Oncology Nursing Society
- Associated public health groups
- Public Health England
- Public Health Wales
- General commentators
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare Products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Alliance
- NHS Commercial Medicines Unit
- NHS Confederation
- Scottish Medicines Consortium
- Relevant research groups
- Cochrane Lung Cancer Group
- Institute of Cancer Research
- MRC Clinical Trials Unit
- National Cancer Research Institute
- National Cancer Research Network
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 18 August 2022 | Discontinued. The company have informed us that they are no longer seeking regulatory approval in this indication. Therefore the appraisal is suspended. |
| 21 June 2017 | Note added to the project documents |
| 08 December 2016 | Invitation to participate |
| 08 June 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual